Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies

Claus Bachert*, Anju T. Peters, Enrico Heffler, Joseph K. Han, Heidi Olze, Oliver Pfaar, Chien Chia Chuang, Raj Rout, Richa Attre, Ledia Goga, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz, Zhen Chen, Siddhesh Kamat, Shahid Siddiqui

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)244-249
Number of pages6
JournalClinical and Experimental Allergy
Volume52
Issue number2
DOIs
StatePublished - Feb 2022

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this